Cover Image
市場調查報告書

OpportunityAnalyzer:卵巢癌 - 市場機會分析與未來預測

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

出版商 GlobalData 商品編碼 530565
出版日期 內容資訊 英文 280 Pages
訂單完成後即時交付
價格
Back to Top
OpportunityAnalyzer:卵巢癌 - 市場機會分析與未來預測 OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025
出版日期: 2017年05月01日 內容資訊: 英文 280 Pages
簡介

卵巢癌是婦女中第五常見的惡性腫瘤,是婦科癌症中死亡的主要原因。由於疾病症狀的非特異性,大多數卵巢癌患者確診時皆已是晚期,預後不高。目前的標準治療(SOC)主要為手術來減輕症狀,再由含鉑類藥物等的化療來抑止病情惡化。在2015年時,全球主要 7個(7MM)卵巢癌市場達到12億3300萬美元的規模,此外預測到2025年前將以年複合成長率 (CAGR) 15%以上的速度成長。

本報告提供卵巢癌的治療藥相關之最新研究·開發趨勢與今後的市場趨勢預測與分析,提供疾病概要和目前的治療方法,未滿足需求·市場機會評估,今後10年的發病數量·市場規模的預測值,臨床試驗的進展,新治療藥的開發平台評估,今後的市場·技術趨勢等調查·預測。

第1章 目錄

第2章 卵巢癌:摘要整理

第3章 簡介

  • 背景情況
  • 相關分析
  • 出版預定的相關分析

第4章 疾病概要

  • 病理和病因
  • 病期分類系統
  • 風險要素,併發症,篩檢
  • 預後·生活品質 (QoL)

第5章 流行病學

  • 疾病的背景情況
  • 風險要素和併發症
  • 全球性趨勢
    • 7MM (主要7個國家)的發病數量趨勢
    • 在7MM的相對生存度趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的假設·手法
    • 未利用之資訊來源
  • 卵巢癌的流行病學的預測 (總計11年份)
    • 卵巢癌的確診發病者數
    • 各年齡層的確診發病者數
    • 年齡已調整的確診發病者數
    • 原發性腹膜癌症的確診發病者數
    • 卵巢癌·原發性腹膜癌症患病人數 (確診後存活5年病患)
  • 議論
    • 流行病學性的預測結果相關考察
    • 分析的限制
    • 分析的優勢

第6章 目前治療選擇

  • 概要
  • 診斷·治療
    • 診斷
    • 治療指南
  • 臨床診療主要的處方藥
  • 產品簡介:領導品牌,血管新生抑制劑
    • Avastin (Bevacizumab)
  • 產品簡介:領導品牌,PARP抑制劑
    • Lynparza (oraparibu)
    • Rubraca (rukaparibu)
    • Zejula (niraparibu)
  • 產品簡介:領導品牌,下一代化療
    • Yondelis (torabekutejin)
  • 非專利化療
    • 最前線治療方法 (佐劑/第一選擇療法)
    • 復發性疾病

第7章 未滿足需求的評估與機會分析

  • 概要
  • 第一選擇療法的改善
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 含鉑類藥物抗性患者之替代性治療選擇
  • 個人化醫療的方法
  • 高度惡性嚴重種類的卵巢癌治療選擇
  • 初期階段的卵巢癌診斷手法

第8章 研究開發 (R&D) 策略

  • 概要
    • 化療的最佳化
    • 標靶治療:配合患者的方法
    • 免疫療法:配合患者的方法
    • 聯合治療
    • 授權合約·企業合作
  • 臨床實驗的設計
    • 目前臨床實驗的試驗指標
    • 未來臨床實驗的試驗指標
    • 復發性疾病臨床實驗招募臨床實驗對象:目前含鉑類藥物反應性/反抗性的範例轉變

第9章 開發平台分析

  • 概要
  • 產品簡介:免疫檢查點調製器
    • Bavencio (Avelumab)
    • Opdivo (Nivolumab)
    • Tecentriq (Atezolizumab)
  • 產品簡介:癌症疫苗
    • Vigil (gemogenovatucel-T)
  • 產品簡介:血管破壞劑
    • fosuburetaburin·torometamin
  • 產品簡介:PARP抑制劑
    • Veliparib
  • 產品簡介:細胞傷害性標靶治療 (抗體·藥物複合體)
  • Mirvetuximab soravtansine
  • 產品簡介:Next-Generation Chemotherapies
    • Opaxio (Paclitaxel·porigurumekusu)
    • Lurbinectedin
    • Apealea/Paclical (Paclitaxel)
  • 初期階段的創新方法
    • 免疫查核點·調製器
    • 腫瘤溶解性病毒
    • 血管新生抑制劑
    • 白細胞介素12促效劑
    • Toll樣受體8 (TLR8) 促效劑
    • 癌症疫苗
    • 激化酵素抑制劑
    • 細胞傷害性標靶治療
    • P53促效劑
  • 臨床實驗階段的其他值得注意醫藥品

第10章 開發平台評估分析

  • 在主要開發平台藥物臨床方面標準
  • 在主要開發平台藥物的商業方面標準
  • 競爭力的評估
  • 主要國家市場未來預測 (今後10年份)
    • 美國
    • (5EU)歐洲主要5個國家
    • 日本

第11章 附錄

圖表一覽

目錄
Product Code: GDHC066POA

Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological cancers. Due to the non-specific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disease, at which point their prognosis is poor. Current standard of care (SOC) therapies focus on primary de-bulking surgery, followed by adjuvant platinum-based chemotherapy or neoadjuvant platinum-based chemotherapy, followed by interval de-bulking surgery and additional cycles of platinum-based chemotherapy, with carboplatin and paclitaxel being the gold standard.

In 2015, the total ovarian cancer market was valued at US$1.233B across the 7MM, with the US accounting for 47.2% of the market. Over the course of the forecast period (till 2025), GlobalData expects the 7MM sales to dramatically increase at a Compound Annual Growth Rate (CAGR) of 15%+.

The key driver of growth within the 7MM ovarian cancer market will be the establishment of new standard of care (SOC) maintenance therapies in the first and second lines of treatment for newly diagnosed and recurrent patients. The anticipated extended durations of therapy in the maintenance settings should fuel the sales of PARP inhibitors and immune checkpoint modulators, as their efficacy data is expected to justify their expensive price tags.

Major drivers of growth in the ovarian cancer market across the 7MM also include the following -

  • Embracing PARP inhibitors into the treatment paradigm of patients will drive growth in the ovarian cancer market, especially through the provision of a targeted therapy option for patients leading to a more personalized approach to disease treatment.
  • A significant contributor to growth in the ovarian cancer market will be the adoption of IO drugs in the treatment of the disease as the paradigm shifts toward treatment choices based on the individual patient.
  • The adoption of maintenance therapy will result in patients receiving drugs for a longer duration, thereby increasing the longevity of product sales compared to those products isolated in the later lines of therapy.

The report "OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025" provides an overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following analysis -

  • Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Companies mentioned in this report: AB Science,AbbVie, Acerta, Aprea, Array BioPharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celsion, Chugai Pharmaceutical, Clovis Oncology, Ganymed, Genentech, Gradalis, ImmunoGen, Immunovaccine, Incyte, Innate Pharma, Janssen, Mateon Therapeutics, MedImmune, Merck & Co., Merck KGaA, Oasmia, Oncolytics Biotech, Ono Phamaceutical, Pfizer, PharmaMar, Prima BioMed, PsiOxus Therapeutics, Roche, Sotio, Taiho Pharmaceutical, Tesaro, VentiRx

Scope:

  • Overview of ovarian cancer, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline ovarian cancer market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting ovarian cancer therapeutics sales in the 7MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the 7MM ovarian cancer therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy:

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the 7MM ovarian cancer therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the ovarian cancer therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Ovarian Cancer: Executive Summary

  • 2.1. Dramatic Growth, Driven by the Establishment of Standard of Care Maintenance Therapies, Is Projected for the 7MM Ovarian Cancer Market from 2015 to 2025
  • 2.2. AstraZeneca, Tesaro, and Clovis are Poised for a Showdown in the PARP Inhibitor Ovarian Cancer Treatment Market for BRCA+, BRCA-like, and All Comers
  • 2.3. Roche Expected to Remain Market Leader on the Heels of Avastin-based Combinations and the 7MM's Second Programmed Death-Ligand 1 Inhibitor, Tecentriq, to Compete with Merck KGaA/Pfizer's First-to-Market Bavencio
  • 2.4. Unmet Need of More Therapies for Recurrent Patients in Later Lines of Therapy, Especially Platinum-Resistant Patients, Anticipated to be Partially Fulfilled, with Opportunities Remaining
  • 2.5. What Do Physicians Think?

3. Introduction

  • 3.1. Catalyst
  • 3.2. Related Reports
  • 3.3. Upcoming Related Reports

4. Disease Overview

  • 4.1. Etiology and Pathophysiology
  • 4.2. Staging Systems
  • 4.3. Risk Factors, Symptoms, and Screening
  • 4.4. Prognosis and Quality of Life

5. Epidemiology

  • 5.1. Disease Background
  • 5.2. Risk Factors and Comorbidities
  • 5.3. Global Trends
    • 5.3.1. 7MM Incidence Trends
    • 5.3.2. 7MM Trends in Relative Survival
  • 5.4. Forecast Methodology
    • 5.4.1. Sources Used Tables
    • 5.4.2. Forecast Assumptions and Methods
    • 5.4.3. Sources Not Used
  • 5.5. Epidemiological Forecast for Ovarian Cancer (2015-2025)
    • 5.5.1. Diagnosed Incident Cases of Ovarian Cancer
    • 5.5.2. Age-Specific Diagnosed Incident Cases of Ovarian Cancer
    • 5.5.3. Age-Standardized Diagnosed Incidence of Ovarian Cancer
    • 5.5.4. Diagnosed Incident Cases of Primary Peritoneal Cancer
    • 5.5.5. Five-Year Diagnosed Prevalent Cases of Ovarian Cancer and Primary Peritoneal Cancer
  • 5.6. Discussion
    • 5.6.1. Epidemiological Forecast Insight
    • 5.6.2. Limitations of the Analysis
    • 5.6.3. Strengths of the Analysis

6. Current Treatment Options

  • 6.1. Overview
  • 6.2. Diagnosis and Treatment
    • 6.2.1. Diagnosis
    • 6.2.2. Treatment Guidelines
  • 6.3. Clinical Practice and Leading Prescribed Drugs
  • 6.4. Product Profiles - Major Brands, Angiogenesis Inhibitors
    • 6.4.1. Avastin (bevacizumab)
  • 6.5. Product Profiles - Major Brands, PARP Inhibitors
    • 6.5.1. Lynparza (olaparib)
    • 6.5.2. Rubraca (rucaparib)
    • 6.5.3. Zejula (niraparib)
  • 6.6. Product Profiles - Major Brands, Next-Generation Chemotherapies
    • 6.6.1. Yondelis (trabectedin)
  • 6.7. Generic Chemotherapy
    • 6.7.1. Front-Line Treatment (Adjuvant/First Line)
    • 6.7.2. Recurrent Disease

7. Unmet Needs Assessment and Opportunity Analysis

  • 7.1. Overview
  • 7.2. Improved First-line Therapies
    • 7.2.1. Unmet Need
    • 7.2.2. Gap Analysis
    • 7.2.3. Opportunity
  • 7.3. Alternative Treatment Options for Platinum-Refractory/Resistant Patients
    • 7.3.1. Unmet Need
    • 7.3.2. Gap Analysis
    • 7.3.3. Opportunity
  • 7.4. Individualized Treatment Approaches
    • 7.4.1. Unmet Need
    • 7.4.2. Gap Analysis
    • 7.4.3. Opportunity
  • 7.5. Therapy Option for Histological Subtypes Beyond High-Grade Serous Ovarian Cancer
    • 7.5.1. Unmet Need
    • 7.5.2. Gap Analysis
    • 7.5.3. Opportunity
  • 7.6. An Early Stage Diagnostic for Ovarian Cancer
    • 7.6.1. Unmet Need
    • 7.6.2. Gap Analysis
    • 7.6.3. Opportunity

8. Research and Development Strategies

  • 8.1. Overview
    • 8.1.1. Optimizing Chemotherapy
    • 8.1.2. Targeted Therapies - A Patient Specific Approach
    • 8.1.3. Immunotherapies - A Patient Specific Approach
    • 8.1.4. Combination Therapies
    • 8.1.5. Licenses and Alliances
  • 8.2. Clinical Trial Design
    • 8.2.1. Current Clinical Trial Endpoints
    • 8.2.2. The Future of Clinical Trial Endpoints
    • 8.2.3. Moving Beyond the Current Platinum Sensitive/Resistant Paradigm for Patient Recruitment in Recurrent Clinical Trials

9. Pipeline Assessment

  • 9.1. Overview
  • 9.2. Product Profiles - Immune Checkpoint Modulators
    • 9.2.1. Bavencio (avelumab)
    • 9.2.2. Opdivo (nivolumab)
    • 9.2.3. Tecentriq (atezolizumab)
  • 9.3. Product Profiles - Cancer Vaccines
    • 9.3.1. Vigil (gemogenovatucel-T)
  • 9.4. Product Profiles - Vascular Disrupting Agents
    • 9.4.1. Fosbretabulin tromethamine
  • 9.5. Product Profiles - PARP Inhibitors
    • 9.5.1. Veliparib
  • 9.6. Product Profiles - Targeted Cytotoxic Therapies (Antibody-Drug Conjugates)
    • 9.6.1. Mirvetuximab soravtansine
  • 9.7. Product Profiles - Next-Generation Chemotherapies
    • 9.7.1. Opaxio (paclitaxel poliglumex)
    • 9.7.2. Lurbinectedin
    • 9.7.3. Apealea/Paclical (paclitaxel)
  • 9.8. Innovative Early Stage Approaches
    • 9.8.1. Immune Checkpoint Modulators
    • 9.8.2. Oncolytic Viruses
    • 9.8.3. Angiogenesis Inhibitors
    • 9.8.4. Interleukin-12 Agonists
    • 9.8.5. Toll-Like Receptor 8 Agonists
    • 9.8.6. Cancer Vaccines
    • 9.8.7. Kinase Inhibitors
    • 9.8.8. Targeted Cytotoxic Therapies
    • 9.8.9. P53 Agonists
  • 9.9. Other Notable Drugs in Clinical Development

10. Pipeline Valuation Analysis

  • 10.1. Clinical Benchmark of Key Pipeline Products
  • 10.2. Commercial Benchmark of Key Pipeline Therapies
  • 10.3. Competitive Assessment
  • 10.4. Top-Line Ten-Year Forecast
    • 10.4.1. US
    • 10.4.2. 5EU
    • 10.4.3. Japan

11. Appendix

  • 11.1. Bibliography
  • 11.2. Abbreviations
  • 11.3. Methodology
  • 11.4. Forecasting Methodology
    • 11.4.1. Percentage of Drug-Treated Patients
    • 11.4.2. Drugs Included in Each Therapeutic Class
    • 11.4.3. Launch and Patent Expiry Dates
    • 11.4.4. General Pricing Assumptions
    • 11.4.5. Average Body Weight and Surface Area Across the 7MM
    • 11.4.6. General Forecast Assumptions
    • 11.4.7. Individual Drug Assumptions
    • 11.4.8. Generic and Biosimilar Erosion
    • 11.4.9. Pricing of Pipeline Agents
  • 11.5. Primary Research
    • 11.5.1. Physicians and Specialists Included in This Study
    • 11.5.2. Online Survey of High-Prescribing Physicians
  • 11.6. About the Authors
    • 11.6.1. Analysts
    • 11.6.2. Epidemiologist
    • 11.6.3. Therapy Area Director
    • 11.6.4. Global Director of Therapy Analysis and Epidemiology
    • 11.6.5. Global Head of Healthcare
  • 11.7. About GlobalData
  • 11.8. Contact Us
  • 11.9. Disclaimer

List of Tables

  • Table 1: Ovarian Cancer: Key Metrics in the 7MM
  • Table 2: FIGO Guidelines: Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum
  • Table 3: FDA Recommendations for Screening Tests for Women and Physicians, 2016
  • Table 4: Risk Factors of OC
  • Table 5: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of OC and PPC
  • Table 6: 7MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of OC and PPC
  • Table 7: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015-2025
  • Table 8: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015
  • Table 9: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015-2025
  • Table 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015-2025
  • Table 11: Treatment Guidelines for Ovarian Cancer in the 7MM
  • Table 12: Preferred Single Agents or Combinations and Other Potentially Active Agents for Ovarian Cancer, by Platinum-Sensitive or Platinum-Resistant Disease
  • Table 13: Product Profile - Avastin
  • Table 14: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer
  • Table 15: Avastin Safety Data from GOG-0218 Study in Newly Diagnosed Ovarian Cancer
  • Table 16: Grade 3 or 4 AEs from GOG-0213 Study in Recurrent Platinum-Sensitive Ovarian Cancer
  • Table 17: Grade ≥3 AEs from AURELIA Study in Recurrent Platinum-Resistant Ovarian Cancer
  • Table 18: Avastin SWOT Analysis in Ovarian Cancer, 2017
  • Table 19: Product Profile - Lynparza
  • Table 20: Efficacy Data for Lynparza Tablets from SOLO2 Trial
  • Table 21: Efficacy Data of Lynparza from Phase III Trial in BRCA-mutated Advanced Ovarian Cancer
  • Table 22: Efficacy Data of Lynparza from Study 19 in Platinum-Sensitive Recurrent BRCA+ Ovarian Cancer
  • Table 23: Most Commonly Reported AEs, Occurring in at Least 15% of Patients in Study 19
  • Table 24: Lynparza SWOT Analysis in Ovarian Cancer, 2017
  • Table 25: Product Profile - Rubraca
  • Table 26: Pooled Efficacy Data of Rubraca from Study 10 and ARIEL2 in BRCA+ Ovarian Cancer
  • Table 27: Most Common AEs Reported in ≥20% of Patients in Study 10 and ARIEL2
  • Table 28: Rubraca SWOT Analysis in Ovarian Cancer, 2017
  • Table 29: Product Profile - Zejula
  • Table 30: Efficacy Data of Zejula from NOVA Study in Platinum-Sensitive Ovarian Cancer
  • Table 31: Summary of the Main Reported AEs in Ovarian Cancer Patients Treated with Zejula
  • Table 32: Zejula SWOT Analysis, Ovarian Cancer 2017
  • Table 33: Product Profile - Yondelis
  • Table 34: Efficacy Data of Yondelis from OVA-301 in Ovarian Cancer
  • Table 35: Most Commonly Reported Grade 3 and 4 AEs in ≥5% of Patients in OVA-301
  • Table 36: Yondelis SWOT Analysis in Ovarian Cancer, 2017
  • Table 37: Key Clinical Trials for Generic Chemotherapies in the Front-Line Setting in Ovarian Cancer
  • Table 38: Key Clinical Trials for Generic IP Chemotherapies in the Front-Line Setting in Ovarian Cancer
  • Table 39: Key Clinical Trials for Dose-Dense Chemotherapy in Ovarian Cancer
  • Table 40: Key Clinical Trials for Ovarian Cancer Neoadjuvant Chemotherapy Treatment
  • Table 41: Key Clinical Trials for Chemotherapy Combinations in Platinum-Sensitive Ovarian Cancer
  • Table 42: Unmet Needs and Opportunities in Ovarian Cancer

Table 43 provides an overview of the key Phase II and III clinical trials being conducted in ovarian cancer. 118

  • Table 44: Potential New Classification System for Recurrent Ovarian Cancer
  • Table 45: Promising Products in Clinical Development for Ovarian Cancer, 2017
  • Table 46: Product Profile - Bavencio
  • Table 47: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016
  • Table 48: Efficacy Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015
  • Table 49: Efficacy Expansion Cohort Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2015
  • Table 50: Safety Data for Bavencio from the JAVELIN Solid Tumor Phase I Trial, 2016
  • Table 51: Bavencio SWOT Analysis, Ovarian Cancer 2017
  • Table 52: Product Profile - Opdivo
  • Table 53: Efficacy Data for Opdivo in Platinum-Resistant Ovarian Cancer (UMIN000005714)
  • Table 54: Treatment-Related AEs of Special Interest in Ovarian Cancer Patients Treated with Opdivo
  • Table 55: Opdivo SWOT Analysis, Ovarian Cancer 2017
  • Table 56: Product Profile - Tecentriq
  • Table 57: Tecentriq SWOT Analysis, Ovarian Cancer 2017
  • Table 58: Product Profile - Vigil (gemogenovatucel-T)
  • Table 59: Efficacy Data for Vigil in Ovarian Cancer from its Ongoing Phase II Trial
  • Table 60: Efficacy and Response Data from a Pooled Data Analysis of Six Vigil Clinical Trials
  • Table 61: Vigil SWOT Analysis, Ovarian Cancer 2017
  • Table 62: Product Profile - Fosbretabulin Tromethamine
  • Table 63: Efficacy Data of GOG-01861 Trial of Fosbretabulin in Ovarian Cancer
  • Table 64: Grade ≥2 AEs Experienced During GOG-01861 in Recurrent Ovarian Cancer
  • Table 65: Fosbretabulin SWOT Analysis, Ovarian Cancer 2017
  • Table 66: Product Profile - Veliparib
  • Table 67: Top-Line Data Summary for the Pivotal Phase II Trials of Avastin in Ovarian Cancer
  • Table 68: AEs Associated with Veliparib in GOG-0280 Clinical Trial
  • Table 69: Veliparib SWOT Analysis, Ovarian Cancer 2017
  • Table 70: Product Profile - Mirvetuximab soravtansine
  • Table 71: Efficacy Data from Phase I Study of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
  • Table 72: Safety Data from Phase I Study of Mirvetuximab Soravtansine in FRα+ Ovarian Cancer
  • Table 73: Mirvetuximab Soravtansine SWOT Analysis, Ovarian Cancer 2017
  • Table 74: Product Profile - Opaxio
  • Table 75: Efficacy Data from GOG-0186C Study in Heavily Pretreated Ovarian Cancer
  • Table 76: Treatment Related AEs for Opaxio from GOG-0186C in Ovarian Cancer
  • Table 77: Opaxio SWOT Analysis, Ovarian Cancer 2017
  • Table 78: Product Profile - Lurbinectedin
  • Table 79: Efficacy Data from Phase II Trial of Lurbinectedin in Platinum-Resistant/Refractory Ovarian Cancer
  • Table 80: Lurbinectedin Treatment in Related AEs in Platinum-Resistant/Refractory Ovarian Cancer
  • Table 81: Lurbinectedin SWOT Analysis, Ovarian Cancer 2017
  • Table 82: Product Profile - Apealea
  • Table 83: Efficacy Data from Phase III Study of Apealea in Platinum-Sensitive Ovarian Cancer
  • Table 84: All Grade AEs Associated with Apealea in Platinum-Sensitive Ovarian Cancer
  • Table 85: Apealea SWOT Analysis, Ovarian Cancer 2017
  • Table 86: Other Innovative Approaches to Ovarian Cancer Management, 2017
  • Table 87: Ovarian Cancer-Specific Clinical Trials Involving Yervoy
  • Table 88: Ovarian Cancer-Specific Clinical Trials Involving Keytruda
  • Table 89: Ovarian Cancer-Specific Clinical Trials Involving Monalizumab
  • Table 90: Ovarian Cancer-Specific Clinical Trials Involving Epacadostat
  • Table 91: Ovarian Cancer-Specific Clinical Trials Involving Durvalumab
  • Table 92: Ovarian Cancer-Specific Clinical Trials Involving Reolysin
  • Table 93: Ovarian Cancer-Specific Clinical Trials Involving Enadenotucirev
  • Table 94: Efficacy of Cediranib from ICON6 Study in Relapsed Platinum-Sensitive Ovarian Cancer
  • Table 95: Summary of Grade ≥3 AEs During ICON6 in Platinum-Sensitive Recurrent Ovarian Cancer
  • Table 96: Cediranib SWOT Analysis, Ovarian Cancer 2017
  • Table 97: Ovarian Cancer-Specific Clinical Trials Involving GEN-1
  • Table 98: Ovarian Cancer-Specific Clinical Trials Involving Motolimod
  • Table 99: Ovarian Cancer-Specific Clinical Trials Involving CVac
  • Table 100: Ovarian Cancer-Specific Clinical Trials Involving DCVAC/OvCa
  • Table 101: Ovarian Cancer-Specific Clinical Trials Involving DPX-Survivac
  • Table 102: Ovarian Cancer-Specific Clinical Trials Involving Binimetinib
  • Table 103: Ovarian Cancer-Specific Clinical Trials Involving Vargatef
  • Table 104: Ovarian Cancer-Specific Clinical Trials Involving Masitinib
  • Table 105: Ovarian Cancer-Specific Clinical Trials Involving Acalabrutinib
  • Table 106: Ovarian Cancer-Specific Clinical Trials Involving IMAB-027
  • Table 107: Ovarian Cancer-Specific Clinical Trials Involving APR-246
  • Table 108: Other Notable Ovarian Cancer Products in Development, 2017
  • Table 109: Clinical Benchmarking of Key Marketed and Pipeline Products
  • Table 110: Clinical Benchmarking of Key Marketed and Pipeline Products, Continued
  • Table 111: Commercial Benchmarking of Key Marketed and Pipeline Products
  • Table 112: Commercial Benchmarking of Key Marketed and Pipeline Products, Continued
  • Table 113: Top-Line Sales Forecasts for Ovarian Cancer Products, 2015-2025 ($M)
  • Table 114: Key Events Impacting Sales for Ovarian Cancer Products, 2015-2025
  • Table 115: Ovarian Cancer Products Market - Drivers and Barriers, 2015-2025
  • Table 116: Ovarian Cancer Patient Population segmentations in the 7MM - Secondary Sources Leveraged
  • Table 117: Ovarian Cancer Marketed and Pipeline Products by Therapeutic Class
  • Table 118: Historical and Projected Launch Dates for Key Drugs in Ovarian Cancer Across the 7MM
  • Table 119: Patent Expiry Dates of Key Drugs in Ovarian Cancer Across the 7MM
  • Table 120: Average Body Weight and Surface Area Across the 7MM
  • Table 121: Average Cost of Therapy of Avastin in the 7MM
  • Table 122: Average Cost of Therapy of Lynparza in the 7MM
  • Table 123: Average Cost of Therapy of Rubraca in the US and 5EU
  • Table 124: Average Cost of Therapy of Yondelis in the 7MM
  • Table 125: Average Cost of Therapy of Votrient in the 7MM
  • Table 126: Average Cost of Therapy of Zejula in the US and 5EU
  • Table 127: Average Cost of Therapy of Veliparib in the 7MM
  • Table 128: Average Cost of Therapy of Bavencio in the 7MM
  • Table 129: Average Cost of Therapy of Tecentriq in the 7MM
  • Table 130: Average Cost of Therapy of Opdivo in the 7MM
  • Table 131: Average Cost of Therapy of Vigil in the 7MM
  • Table 132: Average Cost of Therapy of Lurbinectedin in the 7MM
  • Table 133: Average Cost of Therapy of Fosbretabulin in the US and 5EU
  • Table 134: Average Cost of Therapy of Mirvetuximab Soravtansine in the 7MM
  • Table 135: Average Cost of Therapy of Apealea in the US and 5EU
  • Table 136: High-Prescribing Physicians Surveyed, by Country

List of Figures

  • Figure 1: 7MM Sales from Therapeutic Agents by Region, 2015 and 2025
  • Figure 2: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017
  • Figure 3: Selected Types of Ovarian Cancer and Other Closely Related Neoplasms
  • Figure 4: Risk Factors and Symptoms Suggestive of Ovarian Cancer
  • Figure 5: 7MM, Diagnosed Incidence Rate of OC, Cases per 100,000, All Ages, Women, 1998-2007
  • Figure 6: 7MM, Diagnosed Incident Cases of OC, Ages ≥18 Years, N, 2015-2025
  • Figure 7: 7MM, Age-Specific Diagnosed Incident Cases of OC, N (Row %), 2015
  • Figure 8: 7MM, Age-Standardized Diagnosed Incidence of OC, Ages≥18 Years, Cases per 100,000, 2015
  • Figure 9: 7MM, Diagnosed Incident Cases of PPC, Ages ≥18 Years, N, 2015-2025
  • Figure 10: 7MM, Five-Year Diagnosed Prevalent Cases of OC and PPC, Ages ≥18 Years, N, 2015-2025
  • Figure 11: Top-Level Treatment Flow Chart for Ovarian Cancer Patients
  • Figure 12: Clinical Development Program for Avastin in Ovarian Cancer
  • Figure 13: Clinical Development Program for Lynparza in Ovarian Cancer
  • Figure 14: Clinical Development Program for Rubraca in Ovarian Cancer
  • Figure 15: Clinical Devlopment Program for Zejula in Ovarian Cancer
  • Figure 16: Clinical Development Program for Yondelis in Ovarian Cancer
  • Figure 17: Clinical Development Program for Bavencio in Ovarian Cancer
  • Figure 18: Clinical Development Program for Opdivo in Ovarian Cancer
  • Figure 19: Clinical Development Program for Tecentriq in Ovarian Cancer
  • Figure 20: Clinical Development Program for Vigil in Ovarian Cancer
  • Figure 21: Clinical Development Program for Fosbretabulin in Ovarian Cancer
  • Figure 22: Clinical Development Program for Veliparib in Ovarian Cancer
  • Figure 23: Clinical Development Program for Mirvetuximab Soravtansine in Ovarian Cancer
  • Figure 24: Clinical Development Program for Opaxio in Ovarian Cancer
  • Figure 25: Clinical Development Program for Lurbinectedin in Ovarian Cancer
  • Figure 26: Clinical Development Program for Apealea in Ovarian Cancer
  • Figure 27: Clinical Development Program for Cediranib in Ovarian Cancer
  • Figure 28: Competitive Assessment of Key Ovarian Cancer Pipeline Products, 2017
  • Figure 29: Sales for Ovarian Cancer Products by Region, 2015-2025
Back to Top